ERBB2 and breast carcinoma: Given that a) endosomal localization of HER2 correlates with therapy resistance [38] and b) SorLA mediates HER2 endosomal trafficking [18], determining co‐localization between SorLA and HER2 might have prognostic value in HER2‐positive breast cancer.